Is Apollomics, Inc. (APLM) a Buy, Sell, or Hold?
NASDAQ : APLM
Apollomics, Inc.
$19.19 USD
$3.49 (22.23%)
- Volume
- 34.21K
- Average Volume
- 15.32K
- Market Capitalization
- $21.17M
- P/E Ratio
- -2.54
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $42.12
- Year Low
- $3.66
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.96
| Source | Headline |
|---|---|
|
Apollomics Regains Full Compliance with Nasdaq Listing Requirements
FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that on July 8, 2026, it received written notice from the Nasdaq Listing Qualifications Staff (Staff) stating that the Company regained compliance with the Market Value of Listed Securities (MVLS) requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (Rule) for continued listing on the Nasdaq Capital Market, and the matter is now closed. globenewswire.com - 2026-07-13 08:00:00 |
|
Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia
FOSTER CITY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that it has received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated June 18, 2026 stating that the Company is not in compliance with the requirement to maintain a minimum Market Value of Listed Securities (“MVLS”) of $35 million as set forth under Nasdaq Listing Rule for continued listing on The Nasdaq Capital Market. globenewswire.com - 2026-06-24 16:15:00 |
|
Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress
Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential. To date, more than 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials. globenewswire.com - 2026-04-27 08:00:00 |
